Dr. Evan Raff, M.D
NPI: 1346581923
Total Payments
$30,595
2021 Payments
$30,323
Companies
5
Transactions
30
Medicare Patients
494
Medicare Billing
$9,789
Payment Breakdown by Category
Research$30,323 (99.1%)
Food & Beverage$271.36 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30,323 | 26 | 99.1% |
| Food and Beverage | $271.36 | 4 | 0.9% |
Payments by Type
Research
$30,323
26 transactions
General
$271.36
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $30,323 | 26 | $0 (2021) |
| Ethicon US, LLC | $104.12 | 1 | $0 (2018) |
| Biocompatibles, Inc. | $66.65 | 1 | $0 (2018) |
| Boston Scientific Corporation | $54.20 | 1 | $0 (2018) |
| Ethicon Endo-Surgery Inc. | $46.39 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $30,323 | 26 | Exelixis Inc. ($30,323) |
| 2018 | $224.97 | 3 | Ethicon US, LLC ($104.12) |
| 2017 | $46.39 | 1 | Ethicon Endo-Surgery Inc. ($46.39) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,908.00 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 12/29/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $1,030.50 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 11/18/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $940.50 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 11/18/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $787.50 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 10/25/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,629.00 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 10/25/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $641.25 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 09/23/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $1,494.00 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 09/23/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,363.50 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 08/25/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $2,319.75 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 08/25/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $542.25 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 07/26/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,633.50 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 07/26/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $297.00 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 06/30/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,406.25 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 06/30/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $162.00 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 06/30/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $72.00 | Research |
| Study: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer • Category: Oncology | ||||||
| 05/24/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,208.25 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 05/24/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $452.25 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 04/26/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $2,875.50 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 04/26/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $1,746.00 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 04/26/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $697.50 | Research |
| Study: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer • Category: Oncology | ||||||
| 03/22/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $1,383.75 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 03/22/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $441.00 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 02/17/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $2,034.00 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
| 02/17/2021 | Exelixis Inc. | Cabometyx (Drug) | — | Cash or cash equivalent | $1,336.50 | Research |
| Study: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors • Category: Oncology | ||||||
| 01/25/2021 | Exelixis Inc. | — | — | Cash or cash equivalent | $987.75 | Research |
| Study: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Exelixis Inc. | $19,537 | 12 |
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Exelixis Inc. | $10,017 | 12 |
| A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer | Exelixis Inc. | $769.50 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 52 | 53 | $2,822 | $639.40 |
| 2020 | 9 | 442 | 466 | $43,971 | $9,149 |
Total Patients
494
Total Services
519
Medicare Billing
$9,789
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70450 | Ct scan head or brain | Facility | 2021 | 11 | 11 | $1,562 | $354.28 | 22.7% |
| 71045 | X-ray of chest, 1 view | Facility | 2021 | 41 | 42 | $1,260 | $285.12 | 22.6% |
| 71045 | X-ray of chest, 1 view | Facility | 2020 | 282 | 304 | $9,120 | $2,309 | 25.3% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2020 | 27 | 29 | $11,890 | $2,167 | 18.2% |
| 70450 | Ct scan head or brain | Facility | 2020 | 39 | 39 | $5,538 | $1,196 | 21.6% |
| 71275 | Ct scan of blood vessels in chest with contrast | Facility | 2020 | 13 | 13 | $4,160 | $801.54 | 19.3% |
| 74176 | Ct scan of abdomen and pelvis | Facility | 2020 | 11 | 11 | $4,235 | $748.42 | 17.7% |
| 76770 | Ultrasound behind abdominal cavity | Facility | 2020 | 20 | 20 | $2,440 | $533.78 | 21.9% |
| 76705 | Ultrasound of abdomen | Facility | 2020 | 22 | 22 | $2,156 | $526.78 | 24.4% |
| 76700 | Ultrasound of abdomen | Facility | 2020 | 16 | 16 | $2,128 | $483.42 | 22.7% |
| 72125 | Ct scan of upper spine | Facility | 2020 | 12 | 12 | $2,304 | $383.26 | 16.6% |
About Dr. Evan Raff, M.D
Dr. Evan Raff, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2013. The National Provider Identifier (NPI) number assigned to this provider is 1346581923.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Evan Raff, M.D has received a total of $30,595 in payments from pharmaceutical and medical device companies, with $30,323 received in 2021. These payments were reported across 30 transactions from 5 companies. The most common payment nature is "" ($30,323).
As a Medicare-enrolled provider, Raff has provided services to 494 Medicare beneficiaries, totaling 519 services with total Medicare billing of $9,789. Data is available for 2 years (2020–2021), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Diagnostic Radiology
- Location Los Angeles, CA
- Active Since 03/07/2013
- Last Updated 12/03/2018
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346581923
Products in Payments
- Cabometyx (Drug) $10,787
- CERTUS 140 MICROWAVE ABLATION SYSTEM (Device) $104.12
- THERASPHERE - BIO (Device) $66.65
- GENERAL NONVASCULAR INTERVENTION (Device) $54.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Los Angeles
Dr. Sadeea Abbasi, M.d., Ph.d, M.D., PH.D
Student in an Organized Health Care Education/Training Program — Payments: $394,199
Student in an Organized Health Care Education/Training Program $394,199
Dr. Edward Nomoto, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $376,152
Student in an Organized Health Care Education/Training Program $376,152
Dr. Matthew Herrmann, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $248,245
Student in an Organized Health Care Education/Training Program $248,245
Chanook Ahn, Dmd, DMD
Student in an Organized Health Care Education/Training Program — Payments: $233,441
Student in an Organized Health Care Education/Training Program $233,441
Dr. Sina Tebi, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $226,858
Student in an Organized Health Care Education/Training Program $226,858
Arjan Hura, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $188,267
Student in an Organized Health Care Education/Training Program $188,267